Sipuleucel-T (Provenge), an immunotherapy tailor-made for men with metastatic castration-resistant prostate cancer (mCRPC) using their own white blood cells, is just as potent if it is manufactured while a patient is taking enzalutamide (Xtandi), and the two drugs seem to boost immunity more effectively when administered together.
- A Network of Your PeersView more >>
Most Popular Right Now
Dr Richard Michaelson and Kimberly Blackwell, MD discuss their decision-making processes when treating patients with metastatic HR+/HER2- breast cancer. View Now